



2015

# Identifying Molecular Features Associated with Psychoneurological Symptoms in Women with Breast Cancer Using Multivariate Mixed Models

Qing Zhou

*Virginia Commonwealth University, [zhouq3@vcu.edu](mailto:zhouq3@vcu.edu)*

Colleen Jackson-Cook

*Virginia Commonwealth University, [ccook@mcvh-vcu.edu](mailto:ccook@mcvh-vcu.edu)*

Debra Lyon

*University of Florida*

Robert Perera

*Virginia Commonwealth University*

Kellie Archer

*Virginia Commonwealth University, [kjarcher@vcu.edu](mailto:kjarcher@vcu.edu)*

Follow this and additional works at: [http://scholarscompass.vcu.edu/bios\\_pubs](http://scholarscompass.vcu.edu/bios_pubs)

 Part of the [Medicine and Health Sciences Commons](#)

Copyright © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

Downloaded from

[http://scholarscompass.vcu.edu/bios\\_pubs/34](http://scholarscompass.vcu.edu/bios_pubs/34)

This Article is brought to you for free and open access by the Dept. of Biostatistics at VCU Scholars Compass. It has been accepted for inclusion in Biostatistics Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact [libcompass@vcu.edu](mailto:libcompass@vcu.edu).

# Identifying Molecular Features Associated with Psychoneurological Symptoms in Women with Breast Cancer Using Multivariate Mixed Models

Qing Zhou<sup>1</sup>, Colleen Jackson-Cook<sup>2</sup>, Debra Lyon<sup>3</sup>, Robert Perera<sup>4</sup> and Kellie J. Archer<sup>1</sup>

<sup>1</sup>Department of Biostatistics, <sup>2</sup>Department of Pathology, Virginia Commonwealth University, Richmond, VA, USA. <sup>3</sup>College of Nursing, University of Florida, Gainesville, FL, USA. <sup>4</sup>Departments of Biostatistics & Social and Behavioral Health, Virginia Commonwealth University, Richmond, VA, USA.

## Supplementary Issue: Computer Simulation, Bioinformatics, and Statistical Analysis of Cancer Data and Processes

**ABSTRACT:** Breast cancer (BC) is the second most common cancer among women. Research shows many women with BC experience anxiety, depression, and stress (ADS). Epigenetics has recently emerged as a potential mechanism for the development of depression.<sup>1</sup> Although there are growing numbers of research studies indicating that epigenetic changes are associated with ADS, there is currently no evidence that this association is present in women with BC. The goal of this study was to identify high-throughput methylation sites (CpG sites) that are associated with three psychoneurological symptoms (ADS) in women with BC. Traditionally, univariate models have been used to examine the relationship between methylation sites and each psychoneurological symptom; nevertheless, ADS can be treated as a cluster of related symptoms and included together in a multivariate linear model. Hence, an overarching goal of this study is to compare and contrast univariate and multivariate models when identifying methylation sites associated with ADS in women with BC. When fitting separate linear regression models for each ADS scale, 3 among 285,173 CpG sites tested were significantly associated with depression. Two significant CpG sites are located on their respective genes *FAM101A* and *FOXJ1*, and the third site cannot be mapped to any known gene at this time. In contrast, the multivariate models identified 8,535 ADS-related CpG sites. In conclusion, when analyzing correlated psychoneurological symptom outcomes, multivariate models are more powerful and thus are recommended.

**KEYWORDS:** breast cancer, mixed model, methylation, stress, anxiety, depression

**SUPPLEMENT:** Computer Simulation, Bioinformatics, and Statistical Analysis of Cancer Data and Processes

**CITATION:** Zhou et al. Identifying Molecular Features Associated with Psychoneurological Symptoms in Women with Breast Cancer Using Multivariate Mixed Models. *Cancer Informatics* 2015;14(S2) 139–145 doi: 10.4137/CIN.S17276.

**RECEIVED:** November 26, 2014. **RESUBMITTED:** February 15, 2015. **ACCEPTED FOR PUBLICATION:** February 17, 2015.

**ACADEMIC EDITOR:** J.T. Efrid, Editor in Chief

**TYPE:** Original Research

**FUNDING:** Research reported in this publication was supported by the National Library of Medicine of the National Institutes of Health under Award Number R01LM011169. Data collection was supported by the National Institute of Nursing Research of the National Institute of Health under Award Number R01NR012667. Services in support of the research project were generated by the VCU Massey Cancer Center Biostatistics Shared Resource, supported, in part, with funding from NIH-NCI Cancer Center Support Grant P30 CA016059. The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal.

**DISCLAIMER:** The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**COMPETING INTERESTS:** Authors disclose no potential conflicts of interest.

**CORRESPONDENCE:** zhouq3@vcu.edu

**COPYRIGHT:** © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

Paper subject to independent expert blind peer review by minimum of two reviewers. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).

Published by Libertas Academica. Learn more about this journal.

## Introduction

Breast Cancer (BC) is the second most common cancer among women. Research shows that many women with BC experience major depression and generalized anxiety disorder.<sup>2</sup> Significantly higher incidences of post-traumatic stress disorder and higher scores on emotional distress were also observed in women with breast cancer.<sup>3</sup> One well-studied biological mechanism leading to anxiety, depression, and stress (ADS) is cytokine-induced behavioral changes in sick individuals.<sup>4</sup> There are both clinical and experimental evidence indicating that activation of the brain cytokine system is related to depression.<sup>4</sup> Cytokine activation not only relates to depression but also to cancer development.<sup>4</sup> Lyon et al have shown that many groups of cytokines were elevated in women with BC.<sup>5</sup>

Another biological change (other than cytokine activation) that has recently emerged as a potential mechanism for the

development of depression is epigenetics.<sup>1</sup> DNA methylation can prevent enzymes from binding to the promoter region of a gene and thereby cause up- or down-regulation of DNA transcription,<sup>1</sup> with these effects potentially being present for sites throughout the genome. An alternative means for altering the expression of genes is through position effects for genes localized near the telomere (the ends of the chromosomes).<sup>6,7</sup> As telomeres shorten, the reduction of heterochromatin could result in alterations in chromatin conformation, which leads to changes in the expression of nearby genes.<sup>8,9</sup> Furthermore, shortening of telomeres is associated with increased levels of chromosomal instability, which, in turn, could lead to alterations in gene expression. It has been shown that accelerated telomere shortening is associated with psychosocial stress,<sup>10</sup> and that hypermethylation is associated with panic disorder.<sup>11</sup> Although there are growing numbers of research



studies indicating that epigenetic changes are associated with ADS, there is currently no evidence that this association is present in women with BC.

The goal of this study is to identify methylation patterns that are associated with three psychoneurological symptoms, ADS, in women with BC. A commonly used and well-validated questionnaire to measure anxiety and depression is the Hospital Anxiety and Depression Scale (HADS),<sup>12</sup> and a widely used and well-validated instrument for measuring perceived stress is the Perceived Stress Scale (PSS).<sup>13</sup> Genome-wide methylation was assessed using the high-throughput Illumina Human Methylation 450K assay.

Traditionally, univariate models have been used to examine the relationship between molecular features and each outcome variable (ADS); nevertheless, analyzing multiple outcome variables globally has become more frequent in many fields of biomedical research.<sup>14</sup> In fact, this approach is especially helpful for evaluating traits that appear related. For example, evidence that stress is related to depression and anxiety in women with BC comes from the results of a study by Varni et al, who found that higher levels of perceived stress were associated with increased depression and anxiety among survivors of childhood cancer.<sup>15</sup> Therefore, instead of fitting separate univariate models to each psychoneurological symptom, ADS can be treated as a cluster of related symptoms and included together in a multivariate linear model. Hence, an overarching goal of this study is to compare and contrast univariate and multivariate models when identifying molecular features associated with ADS in women with BC.

## Methods

**Study design.** The study included 73 women with BC in stage I ( $n = 21$ ), II ( $n = 44$ ), or III ( $n = 8$ ). This research was approved by the Institutional Review Board at Virginia Commonwealth University (VCU IRB #HM 13194) and complied with the principles of the Declaration of Helsinki. The molecular features and ADS were measured at study enrollment, prior to their receiving chemotherapy. The severity of depression and anxiety was measured using the HADS, which is a 14-item questionnaire.<sup>12</sup> Among the 14 items, 7 assess anxiety and 7 assess depression. Each item is on a four-level ordinal scale, the scale response is calculated such that the ordinal levels contribute 0–3 points, and the 14 items within each scale are summed. Using these sums, subjects may be classified as normal (score <8), borderline (8–10), or having clinical anxiety or depression (score >10).<sup>16</sup> Although the scale has an ordered structure, we used the continuous version of HADS in order to maintain all the information in the scale and protect power.

Stress was evaluated using a 10-item PSS.<sup>17</sup> PSS was designed to measure the degree to which situations in one's life are appraised as stressful.<sup>13</sup> Items were designed to monitor how unpredictable, uncontrollable, and overloaded a respondent's

life is by asking about the respondent's feelings and thoughts during the last month.<sup>17</sup> Of the 10 total responses on the PSS, 6 were negative responses and were given the following numerical value: never = 0; almost never = 1; sometimes = 2; fairly often = 3; and very often = 4. The remaining four positive items in the PSS were scored in a reversed format according to standard approaches (ie, never = 4; ...; very often = 0).<sup>18,19</sup> The scores were summed, with the higher total scores of PSS indicating higher overall stress.<sup>17</sup>

The Illumina Human Methylation 450K assay was used to profile human DNA methylation using whole blood from women diagnosed with breast cancer. The  $\beta$ -values were defined as the proportion methylated, and were reported for each CpG site using the *minfi* Bioconductor package<sup>20</sup> in the R programming environment.<sup>21</sup>  $\beta$ -values were plotted against the percentage of GC content across all samples. Based on the results, CpG sites with GC content greater than 40% were filtered out. CpG sites with all  $\beta$ -values over 0.9 or below 0.1 were considered to be constitutively methylated or unmethylated and therefore were excluded from the study.<sup>22</sup> Because single nucleotide polymorphisms (SNPs) may affect the performance of this assay,<sup>23</sup> the CpG sites containing SNPs were also excluded. After filtering, 285,173 CpG sites remained. The Illumina Human Methylation 450K Assay uses two types of probe designs: Infinium I and Infinium II. Peak correction was used to align the M-values produced by the two types of probe designs ( $M\text{-value} = \log(\beta/(1 - \beta))$ ).<sup>24</sup> In this study, five subjects had multiple methylation profiles: because these profiles were highly correlated, the mean methylation levels were used. After taking the average, the M-values were back-transformed into  $\beta$ -values, which were used in the analysis.

**Statistical analysis.** The HADS and PSS scales were first examined using descriptive statistics. To identify the molecular features significantly associated with each of the scales, a linear regression model was fit to each of the 285,173 CpG sites. ADS were treated as three separate continuous responses. The  $P$ -values obtained from the linear regression models were adjusted using the Benjamini–Hochberg (BH) method to control the false discovery rate (FDR). CpG sites with an FDR less than 0.02 were considered to be significant.

The ADS values were plotted against each other to produce a scatterplot matrix. Pearson's correlation among the three scales was also calculated. Based on the results, it seemed reasonable to fit a multivariate linear mixed model by combining all scales. The mixed model included a methylation component, two dummy coded indicators representing the type of psychoneurological symptom with anxiety as referent level, and the interactions between each indicator and the methylation component. In addition, the model included a subject-specific term to account for the correlation among scales. To illustrate the model with a formula, let  $Y_{ij}$  represent the HADS-Anxiety, HADS-Depression, and PSS outcome for  $i$ th subject, where  $j = 1, 2$ , or 3, respectively. The model can then be expressed as

$$Y_{ij} = \alpha + \beta_1 x_{i1} + \beta_2 x_{i2} + \beta_3 x_{i3} + \beta_4 x_{i4} + \beta_5 x_{i5} + b_i + \epsilon_{ij}$$


where  $x_{i1}$  and  $x_{i2}$  are indicators representing depression and stress,  $x_{i3}$  is a methylation component,  $x_{i4}$  is the interaction between depression and the methylation component, and  $x_{i5}$  is the interaction between stress and the methylation component. The  $\alpha$  and the  $\beta$  terms are the intercept and the slope coefficients, respectively,  $b_i$  is the random subject effect, and  $\epsilon_{ij}$  is the sample error. The null hypothesis of no association between the methylation “signature” and ADS across different psychological disorders was tested by the interaction effect. The likelihood ratio tests were used to compute  $P$ -values, and the resulting  $P$ -values were again adjusted using the BH method to control the FDR. In order to compare the performance of the multivariate models versus the separate models, the FDR thresholds used in the multivariate mixed model was set at 0.02.

All statistical analyses were performed using the R programming environment (version 3.0.2) and the lme4 package.<sup>21</sup>

## Results


The means and standard deviations for the three scales are provided in Table 1. The distributions of the three scales are shown in Figure 1. Although the distribution of HADS-Depression is skewed somewhat to the right, based on the Central Limit Theorem, the mean of HADS-depression will follow a Gaussian distribution due to the large sample size ( $n = 73$ ).<sup>25</sup> Pearson’s correlation between anxiety and depression, anxiety and stress, and depression and stress were 0.657, 0.668, and 0.715, respectively, indicating that the three outcome scales were highly correlated; the scatterplot matrix supported this conclusion (Fig. 2).

When fitting separate models for each ADS scale, among 285,173 CpG sites, the sites with Illumina’s CpG loci ID (IlmnID) cg14474520, cg17527195, and cg23431989 were significantly associated with depression (Table 2). Further investigation suggested that the methylation level at sites cg14474520 and cg23431989 were positively associated with depression (slope coefficients: 104.6 and 70.52). However, at site cg17527195, the methylation level was negatively associated with depression (slope coefficient: −39.42). The scatter plots supported this conclusion (Fig. 3). The CpG site cg14474520 is located on gene *FAM101A*, and the CpG site cg23431989 is located on gene *FOXJ1*. Both *FAM101A* and *FOXJ1* are cancer-related genes. It has been shown that down-regulation of *FAM101A* significantly reduces early



**Figure 1.** Density plot of HADS-Anxiety, HADS-Depression, and PSS.

apoptosis in RKO colorectal cancer cells.<sup>26</sup> Recent studies have suggested that *FOXJ1* may be involved in the development of more than one cancer. *FOXJ1* can function as a tumor suppressor in breast cancer.<sup>27</sup> It is also involved in adverse clinical outcome in ovarian cancers.<sup>28</sup> Chen et al found that high expression of *FOXJ1* is associated with prognosis and tumor cell proliferation in hepatocellular carcinoma.<sup>27</sup> The CpG site cg17527195 cannot be mapped to any known genes at this time.



**Figure 2.** Scatterplot matrix of HADS-Anxiety, HADS-Depression, and PSS.

**Table 1.** Means and standard deviations of the three response variables.

	ANXIETY	DEPRESSION	STRESS
Mean	8.411	3.658	16.699
SD	3.523	3.220	8.100

**Abbreviation:** SD, standard deviation.

**Table 2.** Significant CpG sites from the separate models.



	IlmnID	GENE NAME	LOCATION
Anxiety			
Depression	cg14474520	Family with sequence similarity 101, member A ( <i>FAM101A</i> )	12:123346991
	cg17527195	Not associated with a gene	13:48301485
	cg23431989	Forkhead box J1 ( <i>FOXJ1</i> )	17:71649364
Stress			

**Note:** Locations are defined as chromosome:coordinates and are based on NCBI Build 36.

After fitting multivariate models, the *P*-value histograms support the notion that the multivariate model is more powerful in identifying significant CpG sites (Fig. 4). In Figure 4, the observed *P*-values for the CpG sites from the multivariate models are skewed more to the right compared to the three separate models (Fig. 4). The multivariate models identified 8,535 ADS-related CpG sites ( $FDR < 0.02$ ). These 8,535 significant CpG sites are located in different regions including 4,652 open sea (54.5%), 797 CpG islands (9.3%), 622 north shelf (7.3%), 1,099 north shore (12.9%), 518 south shelf (6%), and 847 south shore (9.9%) sites. The CpG islands were defined as DNA sequences with greater than 50% GC bases and more than 60% CpG observed/expected ratio. The 2-kb sequences upstream and downstream of the CpG islands were defined as north and south shores, respectively, and the 2-kb sequences directly upstream and downstream of the shores were referred to as north or south shelves, respectively. DNA methylation sites in regions other than these are annotated as “open sea”.<sup>23</sup>

Smaller numbers of significant sites can be identified by decreasing the FDR threshold ( $FDR = 0.01$ , number of significant sites = 6847;  $FDR = 0.005$ , number of significant sites = 4579;  $FDR = 0.001$ , number of significant sites = 8). The information for the eight significant CpG sites when  $FDR = 0.001$  are shown in Table 3. Of particular interest

among these eight significant sites is cg22749855, which is located within the *SOCS3* gene and is associated with a gene promoter. *SOCS3* is a well-studied oncogene, and hypermethylation of the *SOCS3* promoter is an important regulatory mechanism for ulcerative colitis-related colorectal cancer.<sup>29</sup> Interestingly, ulcerative colitis-related colorectal cancer is a condition that has also been associated with telomere shortening.<sup>30</sup> Using the mouse as a model, researchers have found that the *Sox3* gene is involved in depression in the mouse brain.<sup>31</sup> *SOCS3* has also been shown to play a role in limiting axon regeneration.<sup>32</sup> Another interesting CpG site is cg11334709, which is located within the *PIK3CD* gene. The *PIK3CD* gene is associated with schizophrenia and increased expression of *PIK3CD* has been observed with a variation

**Figure 3.** Scatterplots of HADS-Depression versus  $\beta$ -values for the three significant CpG sites.**Figure 4.** Histograms of observed *P*-values from the CpG site methylation models.

**Notes:** The top three histograms represent the results from univariate models (separate models for anxiety, depression, and stress, respectively). The bottom histogram represents the results from the multivariate model.



**Table 3.** Annotation for eight significant CpG sites from the multivariate models using an FDR threshold of 0.001.

IlmnID	GENE NAME (SYMBOL)	RELATED ADS OR CANCERS	LOCATION
cg11334709	PIK3CD antisense RNA1 ( <i>PIK3CD-AS1</i> ) Phosphatidylinositol-4,5-bisphosphate 3 kinase, catalytic subunit delta ( <i>PIK3CD</i> )	Leukemia <sup>34</sup> Colorectal cancer <sup>35</sup> Mantel cell lymphomas <sup>36</sup> Hodgkin lymphomas <sup>37</sup> Glioblastoma multiforme <sup>38</sup> Schizophrenia <sup>33</sup>	1:9638606
cg08885142			11:68973477
cg03128029	NOP58 ribonucleoprotein ( <i>NOP58</i> )		2:202851533
cg23043143	IQ motif containing E ( <i>IQCE</i> )		7:2578627
cg11996860			8:102160991
cg06655216			12:88143460
cg22749855	Suppressor of cytokine signaling 3 ( <i>SOCS3</i> )	Breast cancer <sup>39</sup> Prostate cancer <sup>40</sup> Pancreatic cancer <sup>41</sup> Gastric cancer <sup>42</sup> Colorectal cancer <sup>29</sup> Depression (mouse model) <sup>31</sup>	17:73865547
cg16704590	ZNF1 antisense RNA 1 ( <i>ZFAS1</i> ) Small nucleolar RNA, C/D box 12B ( <i>SNORD12B</i> ) Small nucleolar RNA, C/D box 12 ( <i>SNORD12</i> )	Breast cancer <sup>43</sup>	20:47330176

**Notes:** Locations are defined as chromosome:coordinates and are based on NCBI Build 36. Related ADS or cancers are the list of cancers or mental illness we found that are related to the particular gene where the significant CpG site is located.

of *ErB4*, a critical neurodevelopmental gene.<sup>33</sup> Figure 5 demonstrates how methylation is differently associated with the three psychoneurological symptoms at these eight significant CpG sites.


Additionally, we examined the robustness of our results by analyzing the modified version of HADS (HADS with items 7, 11, and 12 removed).<sup>16</sup> The modified HADS was able to identify a larger number of significant CpG sites when fitting mixed models using an FDR of 0.02 (10,856 sites). However, the univariate analyses using the modified HADS did

not yield any significant CpG sites when the FDR was 0.02. These results are consistent with the unmodified HADS results, where we found 8,535 CpG sites significant when fitting mixed models but none that were significant univariately for anxiety or PSS, and only three that were significant univariately for depression.

## Discussion

Although HADS is commonly used to measure anxiety and depression, many researchers have argued that HADS suffers from issues such as lack of consensus on an optimal cutpoint for detecting anxiety and depression, problematic fit of some items, and contradictory results regarding optimal dimensional structures.<sup>16</sup> Lambert suggested that, instead of using the original 14 items, removing items 7, 11, and 12 can improve the model fit.<sup>16</sup> Although in this current study the full HADS was analyzed to allow for comparisons of results with other published work, we also analyzed the modified HADS so that the results could be compared with the analysis of the original scale. For our methylation data, both the unmodified and modified HADS were able to identify a larger number of significant CpG sites when fitting mixed models using an FDR of 0.02 (8,535 and 10,856 CpG sites, respectively) in comparison with the univariate models. In fact, the univariate analyses using the modified HADS did not yield any significant CpG sites for anxiety, depression, or perceived stress, which is similar to the unmodified HADS that only detected three CpG sites, all of which were significantly associated with depression.

The sensitivity study conducted by Illumina stated that the Human Methylation 450 Assay is reliable when detecting


**Figure 5.** Scatterplots of combined HADS and PSS versus  $\beta$ -values for the eight significant CpG sites.



a  $\Delta\beta$ -value of at least 0.2.<sup>23</sup> When comparing two groups,  $\Delta\beta$  is the difference between the mean  $\beta$ -values in the two groups. Because our outcome was continuous, we defined  $\Delta\beta$  as the range of  $\beta$ -values. Among three significant CpG sites found by separate models, only cg17527195 had a  $\Delta\beta$  greater than 0.2 (0.22); therefore, caution is needed when investigating the other two sites. Among 8,535 significant CpG sites found by the multivariate models using the unmodified HADS, 6,847 had a  $\Delta\beta$  greater than 0.2 (80%).

The results of our study demonstrate that the multivariate mixed model is more powerful than fitting separate models. Using multivariate models, a larger number of CpG sites were identified as significant. Figure 4 further demonstrated that the *P*-value distribution from the multivariate models was more skewed to the right compared to those from the univariate models, giving rise to more significant findings at a fixed FDR. Therefore, when analyzing correlated psychoneurological symptom outcomes, multivariate models are recommended.

In the future, we will additionally have each patient's cytokine levels assayed using the BioPlex system, telomere lengths using a fluorescent in situ hybridization (FISH)-based assay, and Illumina methylation levels at baseline and at several follow-up time points. The multivariate mixed model approach will likewise be useful for analyzing longitudinally collected data.

## Author Contributions

Conceived of this study: CJC, DL, KJA. Planned the data collection and subject recruitment: CJC, DL. Analyzed the data: QZ, KJA. Wrote the first draft of the manuscript: QZ. Contributed to the writing of the manuscript: CJC, DL, RP, KJA. Agree with manuscript results and conclusions: QZ, CJC, DL, RP, KJA. Jointly developed the structure and arguments for the paper: QZ, KJA. Made critical revisions and approved final version: CJC, DL, RP, KJA. All authors reviewed and approved of the final manuscript.

## REFERENCES

1. Dalton VS, Kolshus E, McLoughlin DM. Epigenetics and depression: return of the repressed. *J Affect Disord*. 2013;155:1–12.
2. Hill J, Holcombe C, Clark L, et al. Predictors of onset of depression and anxiety in the year after diagnosis of breast cancer. *Psychol Med*. 2011;41(07):1429–36.
3. Amir M, Ramati A. Post-traumatic symptoms, emotional distress and quality of life in long-term survivors of breast cancer: a preliminary research. *J Anxiety Disord*. 2002;16(2):191–206.
4. Dantzer R. Cytokine-induced sickness behavior: where do we stand? *Brain Behav Immun*. 2001;15(1):7–24.
5. Lyon DE, McCain NL, Walter J, Schubert C. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. *Nurs Res*. 2008;57(1):51–8.
6. Blackburn EH. Telomere states and cell fates. *Nature*. 2000;408:53–6.
7. Blackburn EH. Switching and signaling at the telomere. *Cell*. 2001;106(6):661–73.
8. Baur JA, Zou Y, Shay JW, Wright WE. Telomere position effect in human cells. *Science*. 2001;292:2075–7.
9. van Deutekom JC, Bakker E, Lemmers RJ, et al. Evidence for subtelomeric exchange of 3.3 kb tandemly repeated units between chromosomes 4q35 and 10q26: implications for genetic counselling and etiology of FSHD1. *Hum Mol Genet*. 1996;5(12):1997–2003.
10. Simon NM, Smoller JW, McNamara KL, et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. *Biol Psychiatry*. 2006;60(5):432–5.
11. Domschke K, Tidow N, Schrempf M, et al. Epigenetic signature of panic disorder: a role of glutamate decarboxylase 1 (GAD1) DNA hypomethylation. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013;46:189–96.
12. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*. 1983;67(6):361–70.
13. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc Behav*. 1983;24:385–96.
14. Lin X, Ryan L, Sammel M, Zhang D, Padungtod C, Xu X. A scaled linear mixed model for multiple outcomes. *Biometrics*. 2000;56(2):593–601.
15. Varni JW, Katz ER, Colegrove R, Dolgin M. Perceived stress and adjustment of long-term survivors of childhood cancer. *J Psychosoc Oncol*. 1994;12(3):1–16.
16. Lambert SD, Pallant JF, Boyes AW, King MT, Britton B, Girgis A. A Rasch analysis of the Hospital Anxiety and Depression Scale (HADS) among cancer survivors. *Psychol Assess*. 2013;25(2):379–90.
17. Cohen S, Williamson G. Perceived stress in a probability sample of the United States. In: Spacapan S, Oskamp S, eds. *The social psychology of health: Claremont Symposium on Applied Social Psychology*. Newbury Park, CA: Sage; 1988:31–67.
18. Innes KE, Selfe TK, Brown CJ, Rose KM, Thompson-Heisterman A. The effects of meditation on perceived stress and related indices of psychological status and sympathetic activation in persons with Alzheimer's disease and their caregivers: a pilot study. *Evid Based Complement Alternat Med*. 2012;2012:927509.
19. Abut YC, Kitapcioglu D, Erkalp K, et al. Job burnout in 159 anesthesiology trainees. *Saudi J Anaesth*. 2012;6(1):46–51.
20. Aryee MJ, Jaffe AE, Corrada-Bravo H, et al. minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics*. 2014;30(10):1363–9.
21. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing; 2013.
22. Zou J, Lippert C, Heckerman D, Aryee M, Listgarten J. Epigenome-wide association studies without the need for cell-type composition. *Nat Methods*. 2014;11(3):309–11.
23. Bibikova M, Barnes B, Tsan C, et al. High density DNA methylation array with single CpG site resolution. *Genomics*. 2011;98(4):288–95.
24. Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F. Evaluation of the Infinium methylation 450K technology. *Epigenomics*. 2011;3(6):771–84.
25. Lumley T, Diehr P, Emerson S, Chen L. The importance of the normality assumption in large public health data sets. *Annu Rev Public Health*. 2002;23:151–69.
26. Kim JC, Ha YJ, Roh SA, et al. Novel single-nucleotide polymorphism markers predictive of pathologic response to preoperative chemoradiation therapy in rectal cancer patients. *Int J Radiat Oncol Biol Phys*. 2013;86(2):350–7.
27. Chen HW, Huang XD, Li HC, et al. Expression of FOXJ1 in hepatocellular carcinoma: correlation with patients' prognosis and tumor cell proliferation. *Mol Carcinog*. 2013;52(8):645–59.
28. Siu MK, Wong ES, Kong DS, et al. Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FOXJ1 and contributes to adverse clinical outcome in ovarian cancers. *Oncogene*. 2013;32(30):3500–9.
29. Li Y, Deuring J, Peppelenbosch MP, Kuipers EJ, Haar C, Woude CJ. IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. *Carcinogenesis*. 2012;33(10):1889–96.
30. Tahara T, Shibata T, Okubo M, et al. Telomere length in non-neoplastic colonic mucosa in ulcerative colitis (UC) and its relationship to the severe clinical phenotypes. *Clin Exp Med*. 2014; [Epub ahead of print].
31. Mingmalairak S, Tohda M, Murakami Y, Matsumoto K. Possible involvement of signal transducers and activators of transcription 3 system on depression in the model mice brain. *Biol Pharm Bull*. 2010;33(4):636–40.
32. Luo X, Park KK. Neuron-intrinsic inhibitors of axon regeneration: PTEN and SOCS3. *Int Rev Neurobiol*. 2012;105:141–73.
33. Law AJ, Wang Y, Sei Y, et al. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110 $\delta$  inhibition as a potential therapeutic strategy. *Proc Natl Acad Sci U S A*. 2012;109(30):12165–70.
34. Goodwin CB, Li XJ, Mali RS, et al. PI3K p110 $\delta$  uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. *Blood*. 2014;123(18):2838–42.
35. Liao WT, Ye YP, Zhang NJ, et al. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2. *J Pathol*. 2014;232(4):415–27.
36. Iyengar S, Clear A, Bódör C, et al. P110 $\alpha$ -mediated constitutive PI3K signaling limits the efficacy of p110 $\delta$ -selective inhibition in mantle cell lymphoma, particularly with multiple relapse. *Blood*. 2013;121(12):2274–84.
37. Meadows SA, Vega F, Kashishian A, et al. PI3K $\delta$  inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. *Blood*. 2012;119(8):1897–900.



38. Luk SK, Piekorz RP, Nürnberg B, Tony To SS. The catalytic phosphoinositol 3-kinase isoform p110 $\delta$  is required for glioma cell migration and invasion. *Eur J Cancer*. 2012;48(1):149–57.
39. Barclay JL, Anderson ST, Waters MJ, Curlewis JD. SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL. *Int J Cancer*. 2009;124(8):1756–66.
40. Kneitz B, Krebs M, Kalogirou C, et al. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. *Cancer Res*. 2014;74(9):2591–603.
41. Reid-Lombardo KM, Fridley BL, Bamlet WR, Cunningham JM, Sarr MG, Petersen GM. Survival is associated with genetic variation in inflammatory pathway genes among patients with resected and unresected pancreatic cancer. *Ann Surg*. 2013;257(6):1096–102.
42. Deng J, Jiao X, Liu H, et al. Lymph node metastasis is mediated by suppressor of cytokine signaling-3 in gastric cancer. *Tumour Biol*. 2013;34(6):3627–36.
43. Askarian-Amiri ME, Crawford J, French JD, et al. SNORD-host RNA Zfasl is a regulator of mammary development and a potential marker for breast cancer. *RNA*. 2011;17(5):878–91.